Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Paclitaxel 4tocilizumab 2pembrolizumab 2atezolizumab 2zansecimab 1tivozanib 1temsirolimus 1spartalizumab 1ridaforolimus 1parsaclisib 1olaparib 1obinutuzumab 1motesanib diphosphate 1liposomal doxorubicin 1itacitinib 1epacadostat 1durvalumab 1birinapant 1Vertebroplasty 1Temozolomide 1TAK-981 1Ramucirumab 1Panobinostat 1Oxaliplatin 1Leucovorin 1Kyphoplasty 1IT-101 1INCB039110 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solid Tumors × tivozanib × Clear all
NCT01369433 2020-09-01

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

AVEO Pharmaceuticals, Inc.

Phase NA Terminated
225 enrolled 7 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡